NEXAGON Trademark

Trademark Overview

On Tuesday, April 5, 2005, a trademark application was filed for NEXAGON with the United States Patent and Trademark Office. The USPTO has given the NEXAGON trademark a serial number of 78602587. The federal status of this trademark filing is REGISTERED AND RENEWED as of Tuesday, May 1, 2018. This trademark is owned by CoDa Therapeutics Limited. The NEXAGON trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, antisense polynucleotides for inflammation and wound healing
nexagon

General Information

Serial Number78602587
Word MarkNEXAGON
Filing DateTuesday, April 5, 2005
Status800 - REGISTERED AND RENEWED
Status DateTuesday, May 1, 2018
Registration Number3490217
Registration DateTuesday, August 19, 2008
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 27, 2005

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, antisense polynucleotides for inflammation and wound healing

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 13, 2005
Primary Code005
First Use Anywhere DateTuesday, April 29, 2008
First Use In Commerce DateTuesday, April 29, 2008

Trademark Owner History

Party NameAMBER OPHTHALMICS INC.
Party Type33 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressALPHARETTA, GA 30009
Party NameEYEVANCE PHARMACEUTICALS LLC
Party Type32 - New Owner After Registration
Legal Entity Type16 - Limited Liability Company
AddressFT. WORTH, TX 76102
Party NameOCUNEXUS THERAPEUTICS, INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92130
Party NameCODA THERAPEUTICS, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92130
Party NameCODA THERAPEUTICS, INC.
Party Type23 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92121
Party NameCODA THERAPEUTICS, INC.
Party Type22 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92121
Party NameCODATHERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92121
Party NameCoDa Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAuckland 1003
NZ
Party NameCoDa Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAuckland 1003
NZ

Trademark Events

Event DateEvent Description
Wednesday, October 28, 2020AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, October 21, 2020ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, January 24, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 24, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, December 12, 2018AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, May 1, 2018NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Tuesday, May 1, 2018REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, May 1, 2018REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, May 1, 2018CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, April 23, 2018TEAS SECTION 8 & 9 RECEIVED
Wednesday, April 11, 2018AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Saturday, August 19, 2017COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, September 26, 2014NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Friday, September 26, 2014REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, September 19, 2014TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Wednesday, August 20, 2014POST REGISTRATION ACTION MAILED - SEC. 8 & 15
Wednesday, August 20, 2014CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, August 5, 2014TEAS SECTION 8 & 15 RECEIVED
Thursday, August 9, 2012TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 19, 2008REGISTERED-PRINCIPAL REGISTER
Wednesday, July 16, 2008LAW OFFICE REGISTRATION REVIEW COMPLETED
Tuesday, July 15, 2008ASSIGNED TO LIE
Tuesday, July 15, 2008ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, June 18, 2008STATEMENT OF USE PROCESSING COMPLETE
Friday, June 13, 2008USE AMENDMENT FILED
Friday, June 13, 2008TEAS STATEMENT OF USE RECEIVED
Wednesday, March 19, 2008EXTENSION 4 GRANTED
Wednesday, March 19, 2008EXTENSION 4 FILED
Wednesday, March 19, 2008TEAS EXTENSION RECEIVED
Wednesday, October 10, 2007AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, October 3, 2007AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, September 26, 2007EXTENSION 3 GRANTED
Tuesday, September 18, 2007EXTENSION 3 FILED
Wednesday, September 19, 2007AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, September 18, 2007TEAS EXTENSION RECEIVED
Friday, March 16, 2007EXTENSION 2 GRANTED
Friday, March 16, 2007EXTENSION 2 FILED
Friday, March 16, 2007TEAS EXTENSION RECEIVED
Wednesday, October 11, 2006EXTENSION 1 GRANTED
Thursday, September 21, 2006EXTENSION 1 FILED
Monday, September 25, 2006EXTENSION RECEIVED WITH TEAS PETITION
Monday, September 25, 2006PETITION TO REVIVE-GRANTED
Monday, September 25, 2006TEAS PETITION TO REVIVE RECEIVED
Tuesday, March 21, 2006NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 27, 2005PUBLISHED FOR OPPOSITION
Wednesday, December 7, 2005NOTICE OF PUBLICATION
Wednesday, November 9, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, November 4, 2005ASSIGNED TO LIE
Tuesday, November 1, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 1, 2005ASSIGNED TO EXAMINER
Friday, August 5, 2005TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 13, 2005NEW APPLICATION ENTERED IN TRAM

Related Keywords

nexagon inflammation wound healing polynucleotides antisense preparations namely pharmaceutical